Bicara Therapeutics Inc. (BCAX) net assets (shareholders' equity)
Bicara Therapeutics Inc. (BCAX) had net assets of $401.45M at the end of fiscal 2025 (December 31, 2025). That is 18.4% lower than the $491.88M of fiscal 2024. Figures as of 18 Nov 2026, 23:36 UTC, from Yahoo Finance.
Key facts
- Net assets, fiscal 2025
- $401.45M
- Change on fiscal 2024
- −18.4%
- Highest on record
- $491.88Mfiscal 2024
- Lowest on record
- -$148.77Mfiscal 2023
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
Bicara Therapeutics Inc. net assets (shareholders' equity), in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $491.88M in fiscal 2024 and the lowest -$148.77M in fiscal 2023.
Net assets by fiscal year
Bicara Therapeutics Inc. net assets (shareholders' equity), year by year
| Fiscal year | Net assets | Change | Year ended |
|---|---|---|---|
| 2025 | $401.45M | 18.4% down | |
| 2024 | $491.88M | — | |
| 2023 | -$148.77M | — | |
| 2022 | -$98.80M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.
How to read it
Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.
Bicara Therapeutics Inc., figure by figure
- Bicara Therapeutics Inc. market cap
- Bicara Therapeutics Inc. revenue
- Bicara Therapeutics Inc. earnings
- Bicara Therapeutics Inc. earnings per share (EPS)
- Bicara Therapeutics Inc. P/E ratio
- Bicara Therapeutics Inc. P/S ratio
- Bicara Therapeutics Inc. P/B ratio
- Bicara Therapeutics Inc. free cash flow
- Bicara Therapeutics Inc. operating margin
- Bicara Therapeutics Inc. dividend
- Bicara Therapeutics Inc. shares outstanding
- Bicara Therapeutics Inc. total debt
- Bicara Therapeutics Inc. cash on hand
- Bicara Therapeutics Inc. total assets
- Bicara Therapeutics Inc. total liabilities
- Bicara Therapeutics Inc. return on equity (ROE)
- Bicara Therapeutics Inc. return on invested capital (ROIC)
Bicara Therapeutics Inc. (BCAX) overview: price, valuation and scorecard
Bicara Therapeutics Inc. net assets (shareholders' equity): questions and answers
What are Bicara Therapeutics Inc.'s net assets?
Bicara Therapeutics Inc. (BCAX) had net assets of $401.45M at the end of fiscal 2025 (December 31, 2025). That is 18.4% lower than the $491.88M of fiscal 2024.
What are the highest and lowest net assets figures on record for Bicara Therapeutics Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $491.88M in fiscal 2024 and the lowest -$148.77M in fiscal 2023.
How is Bicara Therapeutics Inc.'s net assets calculated?
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Bicara Therapeutics Inc. it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: net assets (shareholders' equity)
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Bicara Therapeutics Inc. (BCAX) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/BCAX/net-assets
Underlying data: Yahoo Finance.